A detailed history of Signet Financial Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Signet Financial Management, LLC holds 8,163 shares of VRTX stock, worth $4.1 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
8,163
Previous 8,112 0.63%
Holding current value
$4.1 Million
Previous $3.8 Million 0.16%
% of portfolio
0.49%
Previous 0.52%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$460.0 - $505.78 $23,460 - $25,794
51 Added 0.63%
8,163 $3.8 Million
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $32,210 - $39,813
82 Added 1.02%
8,112 $3.8 Million
Q1 2024

Apr 15, 2024

BUY
$407.69 - $446.08 $49,738 - $54,421
122 Added 1.54%
8,030 $3.36 Million
Q4 2023

Jan 30, 2024

SELL
$343.0 - $410.68 $8,918 - $10,677
-26 Reduced 0.33%
7,908 $3.22 Million
Q3 2023

Oct 25, 2023

SELL
$338.18 - $362.46 $32,465 - $34,796
-96 Reduced 1.2%
7,934 $2.76 Million
Q2 2023

Jul 18, 2023

BUY
$314.42 - $351.91 $11,633 - $13,020
37 Added 0.46%
8,030 $2.83 Million
Q1 2023

Apr 17, 2023

BUY
$283.23 - $323.1 $19,259 - $21,970
68 Added 0.86%
7,993 $2.52 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $30,290 - $34,076
106 Added 1.36%
7,925 $2.29 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $50,384 - $56,217
184 Added 2.41%
7,819 $2.26 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $1.79 Million - $2.23 Million
7,635 New
7,635 $2.15 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $44,505 - $52,454
-201 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $35,579 - $44,913
201 New
201 $44,000
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $137,174 - $173,565
-903 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $9,896 - $11,371
59 Added 6.99%
903 $174,000
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $127,950 - $149,497
844 New
844 $138,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Signet Financial Management, LLC Portfolio

Follow Signet Financial Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signet Financial Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signet Financial Management, LLC with notifications on news.